Biolegend, 480006, MojoSort™ Mouse CD4 T Cell Isolation Kit
100tests
Catalog Number: 480006
Send an RFQ.
Category
| Verified Reactivity | Mouse |
|---|---|
| Formulation | Cocktail: Phosphate-buffered solution containing 0.09% sodium azide, pH 7.2.Streptavidin Nanobeads: Aqueous solution containing BSA and 0.05% sodium azide. |
| Preparation | The antibodies were purified by affinity chromatography, and conjugated with biotin under optimal conditions.Streptavidin Nanobeads: Streptavidin-coated magnetic beads. |
| Storage & Handling | Antibody cocktail and Streptavidin Nanobeads should be stored undiluted between 2°C and 8°C. |
| Application | Cell Separation (MojoSort™) - Quality tested |
| Recommended Usage | 10 µl of antibody cocktail for 1 X 107 cells in 100 µl of buffer. 10 µl Streptavidin Nanobeads for 1 X 107 cells in 100 µl of buffer. |
| Application Notes | This kit is designed for the isolation of untouched CD4+ T cells from lymphoid tissues. Each lot has been individually optimized. Do not mix and match components from different lots or different kits. Antibody or cocktail dilution to use in column: 8X Nanobead dilution to use in columns: 9X |
| Application References(PubMed link indicates BioLegend citation) | Dong L, et al. 2016. Sci. Rep. 6:36598. (PubMed) |
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Product Citations |
|---|
| Du J, et al. 2022. Sci Immunol. 7:eabo5407. PubMed Li L, et al. 2022. Cancer Immunol Res. 10:1475. PubMed Hao S, et al. 2023. EMBO Rep. 24:e56932. PubMed Liu T, et al. 2023. J Neuroinflammation. 20:94. PubMed Park JS, et al. 2023. Nat Commun. 14:2980. PubMed Fernandez-Perez R, et al. 2021. Front Immunol. 12:687443. PubMed Tatsumi N, et al. 2022. STAR Protoc. 3:101845. PubMed Guo H, et al. 2022. Biomaterials. 283:121441. PubMed Hochrein SM, et al. 2022. Cell Metab. 34:516. PubMed Pandey S, et al. 2020. Cell Syst. 11:495. PubMed Pei S, et al. 2021. J Exp Med. 218:. PubMed Lin CH, et al. 2021. J Exp Med. 218:. PubMed Ecker M, et al. 2022. Elife. 11:. PubMed Guzman–Genuino RM, et al. 2020. Front Immunol. 2.429861111. PubMed Dong L, et al. 2017. Sci Rep. 10.1038/srep36598. PubMed Elyada E, et al. 2019. Cancer Discov. 1.140277778. PubMed Pan YG, et al. 2017. Front Immunol. 1.322222222. PubMed Tatsumi N, et al. 2021. Sci Immunol. 6:eabg0336. PubMed Cheng Y, et al. 2020. PLoS Pathog. 16:e1008569. PubMed Bai C, et al. 2020. Mol Ther Oncolytics. 17:9. PubMed Tang X, et al. 2022. Cell Rep. 41:111673. PubMed Kanno T, et al. 2022. Front Immunol. 13:904875. PubMed Bocchini C, et al. 2016. Blood. 128(26):3061-3072. PubMed Woodring T, et al. 2022. iScience. 25:104934. PubMed Yin X, et al. 2020. Cell Rep. 33:108278. PubMed Feng P, et al. 2021. Theranostics. 11:9503. PubMed Kumar V, et al. 2022. JACC Basic Transl Sci. 7:1038. PubMed Jain A, et al. 2020. Nat Immunol. 0.920138889. PubMed Nomura S, et al. 2019. Sci Rep. 9:17335. PubMed Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed Qin J, et al. 2020. Cancer Immunol Res. 8:1426. PubMed |
| Biology Area | Immunology |
|---|
| Molecular Family | CD Molecules |
|---|
| Gene ID | NA |
|---|
| UniProt | View information about CD4 on UniProt.org |
|---|
| Regulatory Status | RUO |
|---|